{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ebe8cc563e3d811bbd2c9d8/5ec41590ecad096a106c54d0?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Genomics of high-risk myeloma","description":"<p>During COMy 2020, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about genomics of high-risk MM.</p><p><br></p><p>Here, Nikhil Munshi highlights the positive shift in survival outcomes of patients with high-risk MM in recent years, owing to emerging treatments and diagnostic techniques. Three major points are discussed:</p><p>1. Who is high risk?</p><p>2. What are the characteristics of high-risk MM?</p><p>3. How do we treat patients with high-risk disease?</p>","author_name":"Scientific Education Support"}